Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

1(33%)

Results Posted

50%(1 trials)

Phase Distribution

Ph phase_3

33%

Ph phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 1Safety & dosage

1(50.0%)

Phase 3Large-scale testing

1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Detailed Status

Completed2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (50.0%)

Phase 31 (50.0%)

Trials by Status

completed267%

recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

recruitingphase_1

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

NCT02140255

completed

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

NCT00977756

completedphase_3

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

NCT00711009

Clinical Trials (3)

Showing 3 of 3 trials

NCT02140255Phase 1

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

Recruiting

NCT00977756

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Completed

NCT00711009Phase 3

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3